United Therapeutics Corporation (UTHR) is a pioneering biotechnology company headquartered in Silver Spring, Maryland, specializing in innovative therapies for chronic conditions, primarily focusing on pulmonary hypertension and organ transplantation. With a robust pipeline that leverages cutting-edge technologies, United Therapeutics is committed to addressing unmet medical needs and improving patient outcomes worldwide. The company's strategic emphasis on expanding its therapeutic portfolio not only enhances its market position but also underscores its potential for sustainable growth and impactful contributions to the healthcare sector. Show more

Location: 1000 SPRING STREET, SILVER SPRING, MD, UNITED STATES, 20910, Silver Spring, MD, 20910, USA | Website: https://www.unither.com | Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC | Sector: HEALTHCARE

Market Cap

21.23B

52 Wk Range

$266.98 - $519.99

Previous Close

$469.49

Open

$467.16

Volume

351,548

Day Range

$466.01 - $475.65

Enterprise Value

17.45B

Cash

1.137B

Avg Qtr Burn

N/A

Insider Ownership

1.85%

Institutional Own.

99.75%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Remunity™ (treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 3	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso DPI™ (inhaled treprostinil) Details Pulmonary Hypertension (PH) WHO Group 1 / (PAH)Pulmonary Hypertension (PH) WHO Group 3	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso (inhaled treprostinil) Details Progressive pulmonary fibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Ralinepag Details Pulmonary arterial hypertension (PAH)	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso (inhaled treprostinil) Details Idiopathic pulmonary fibrosis	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
miroliverELAP Details Acute liver failure	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
UKidney™ Details End-stage renal disease	Phase 1 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Trevyent® (treprostinil sodium) Details Pulmonary Hypertension (PH) WHO Group 1 (PAH)	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Tyvaso (inhaled treprostinil) Details Pulmonary hypertension, Chronic obstructive pulmonary disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.